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Mechanistic multi-stage models are used to analyze lung-cancer mortality after Plutonium ex-
posure in the Mayak-workers cohort, with follow-up until 2008. Besides the established two-stage
model with clonal expansion, models with three mutation stages as well as a model with two dis-
tinct pathways to cancer are studied. The results suggest that three-stage models offer an improved
description of the data. The best-fitting models point to a mechanism where radiation increases the
rate of clonal expansion. This is interpreted in terms of changes in cell-cycle control mediated by
bystander signaling or repopulation following cell killing. No statistical evidence for a two-pathway
model is found. To elucidate the implications of the different models for radiation risk, several expo-
sure scenarios are studied. Models with a radiation effect at an early stage show a delayed response
and a pronounced drop-off with older ages at exposure. Moreover, the dose-response relationship is
strongly nonlinear for all three-stage models, revealing a marked increase above a critical dose.
I. INTRODUCTION
Cancer is a genetic disease. In the widely held theory of
somatic evolution [1], a cell’s path toward the malignant
state is portrayed as a series of mutations or epigenetic
events, lending it successive selective advantages. These
advantages, as summarized in the “hallmarks of cancer”
[2], essentially amount to an increasingly uncontrolled
proliferation.
Those essential features—mutations accompanied by
proliferation—have long been identified as key ingredi-
ents in modeling carcinogenesis. Beginning with the sem-
inal multi-step models by Armitage/Doll and Nordling
[3, 4], this eventually led to the stochastic two-stage
model with clonal expansion due to Moolgavkar, Ven-
zon, and Knudson [5, 6], which has by now become an
established tool to understand and predict cancer risk
[7–9].
What fundamentally distinguishes such mechanistic
models from conventional epidemiological ones is that
they do not directly model the endpoint—say, the cancer
mortality rate—but rather the process thought to lead
to it, parametrized via mutation and proliferation rates.
This may prove useful especially when the mortality rate
is highly convoluted by an exposure to carcinogens such
as ionizing radiation, as is the case in this study.
Such a mechanistic approach can be readily generalized
so as to build in known biological effects, such as multi-
ple genetic pathways [7, 10] or a more realistic number
of stages [11, 12]. Indeed, for colorectal cancer, where
the understanding of the cellular mechanisms is compar-
atively advanced [13, 14], a number of extended models
have been put forward to account for the role of genomic
instability [10, 15–17], the rather large number of prema-
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lignant stages [12, 18], as well as the intricate dynamics
during progression [19].
By contrast, far less is known regarding other cancer
types. For lung cancer, mechanistic modeling studies are
abundant but have focused almost exclusively on the two-
stage model. These indicate that for the two main risk
factors, smoking [20–22] and α-particle radiation (most
relevant being Radon decay products) [23–32], the best
description is afforded by an enhancement of the prolif-
eration rate of premalignant cells. However, for radia-
tion, this conclusion has been disputed [33] because it
lacks a conclusive biological mechanism, in contrast to
the accepted mutagenic effect of radiation. This debate
has been further sparked by the single analysis to date
going beyond the two-stage model [34]. Comparing fits
to the Colorado-miners data using the two-stage model
with those from a subclass of three-stage models, the au-
thors suggested that a proliferation effect were confined
to the two-stage model, whereas a better fit quality was
achieved within a three-stage framework with a muta-
tional radiation action.
The objective of this paper is to perform a com-
parative analysis of lung-cancer risk associated with α-
radiation using different multi-stage models – specifically
two- and three-stage models as well as a two-path model
for (radiation-induced) genomic instability. Our goal is
to identify the mechanisms of radiation action suggested
by those models, as well as to lay out to what extent
their predicted radiation risks are consistent. To this
end, we apply these models to the Mayak-workers cohort
[35, 36]. These workers, employed at the formerly So-
viet Plutonium-production plant, have been exposed to
substantial doses of 239Pu via inhalation and exhibit a
large number of lung-cancer deaths, 895 in total [37]. A
notable feature of Plutonium exposure is its strong pro-
traction, which might facilitate the assessment of risk on
the long time scales relevant to indoor Radon. Further-
more, information on the strongest risk factor, smoking,
is available for most workers. We will show that certain
2three-stage models give an improved description of the
data, and we elucidate how these lead to predictions for
the risk that are qualitatively different from both two-
stage mechanistic and standard descriptive models.
II. MATERIALS AND METHODS
A. Mayak-workers cohort
The Mayak-workers cohort comprises nuclear workers
at the Mayak Plutonium-production facility at Ozyorsk,
Russia [35]. The current follow-up includes all years
1948–2008 and comprises 25,757 members, cf. Ref. [37]
for a comprehensive overview.
Many of the workers have been exposed to Plutonium-
239, predominantly through inhalation. These inter-
nal doses have been assessed via urine measurements
combined with biokinetic modeling for about 40% of
workers in the plants at risk [38]. Exposure to ex-
ternal gamma radiation has been recorded via film-
badge dosimeters [39], and average annual dose rates
are available for all workers. Furthermore, for most
workers, information exists on smoking status (non-
/eversmoker) as well as on alcohol consumption (teeto-
taler/light/medium/heavy/chronic), see below. Owing
to pronounced smoking and Plutonium-inhalation pat-
terns, the dominant cancer-mortality endpoint is lung
cancer (defined here as ICD-9 code 162), with a total
of 895 mortality cases.
1. Cohort definition
To obtain a sufficiently homogeneous data set
amenable to mechanistic modeling, several selection cri-
teria have been applied, similar to previous studies
[31, 32]. Our reduced (sub)cohort excludes females, since
these make up less than 25% of the whole cohort and ex-
hibit very different mortality rates. Moreover, full infor-
mation is required on smoking/alcohol status and annual
internal dose(rate)s – i.e., 239Pu doses must be measured
or assumed to vanish (for workers outside the radiochem-
ical and Pu plants).[67]
Finally, the follow-up period is restricted as follows. If
a Pu measurement has been performed at time tPu, then
the entry date is set to tPu + 2a. This is done to avoid
selection bias, specifically healthy-survivor effects (due
to extended follow-up periods for persons surviving until
tPu) and diagnostic bias (in case the measurement has
been caused by imminent health problems). To ensure
complete follow-up, the exit date is cut off at the end of
2008 or, in the case of migrants, 2003.
The reduced cohort includes 8,604 persons and 388
lung-cancer deaths.
2. Risk factors
Let us briefly highlight some aspects of the major risk
factors (see Ref. [37] for details). The main interest here
is in internal radiation, with measured nonzero doses
available for 3,667 persons. Due to slow degradation in
the lungs and the long half-life of 239Pu, exposures are
highly protracted: First exposure peaks around age 20,
and typically continues until the end of follow-up. Cumu-
lative lung doses are well described by a log-normal dis-
tribution. Among those measured, it is peaked at 4mGy,
much below the mean dose D¯ = 0.12Gy. Restricted
to lung-cancer cases, the dose distribution is shifted to
higher values, with D¯ = 0.44Gy and lower/upper 5%
quantiles of 7.6mGy and 2.3Gy.
The overall smoking fraction is about 3/4. Alcohol sta-
tus, although not known to be a risk factor for lung can-
cer, may serve as an indicator for smoking habits because
the fraction of smokers increases with alcohol consump-
tion. We group heavy/chronic drinkers as one category,
a = 1, and otherwise set a = 0.
As with any cancer, age is a crucial intrinsic risk fac-
tor. The ages of cohort members range broadly between
about 18 and 81 years, as defined by the lower/upper 5%
quantiles of entry/exit age, with an average of 27 years
spent in the cohort. By contrast, 90% of lung-cancer
cases are found only between ages 49− 78, with a mean
cancer age of 65 years.
3. Ethics statement
The study of the Mayak-workers cohort has been re-
viewed and approved by the Southern Urals Biophysics
Institute’s Review Board for issues related to privacy and
personal data protection.
B. Statistical analysis
1. Multi-stage models
Different multi-stage models are applied to the data.
Their common rationale is to radically reduce the com-
plexity of carcinogenesis to essentially two key processes:
(i) mutations—or, generally, a series of (epi-)genetic
transitions from healthy via pre-malignant to malignant
stem-like cells— and (ii) proliferation (i.e., symmetric di-
vision; cell inactivation or death) of pre-malignant cells
with a selective advantage [40].[68]
Mathematically, this is modeled as continuous-time
Markov processes for the (stochastic) numbers of cells,
Xi(t), at the different stages (i = 0, . . . , k). Specifi-
cally, at age t = 0, one starts with X0 ≡ N healthy
cells, which can make a transition (modeled as a Pois-
son process) with rate µ0 to a first, premalignant stage,
X1.[69] These cells can then undergo a birth/death pro-
cess with rates α1/β1 , leading to a net proliferation rate
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Figure 1: Schematic structure of a k-stage model (top)
and the two-path model studied in this paper (below).
Here, Xj denotes the stochastic number of cells at stage
j, with arrows indicating transitions at rates µj , etc.
(see text). Cancer is assumed to occur once the first
malignant cell appears, with latency period tlag ∼ 5
years.
γ1 ≈ α1 − β1. Further transitions eventually lead to ma-
lignant cells, Xk. The occurrence of the first malignant
cell is assumed to lead to cancer after an effective lag time
tlag, typically on the order of a few years. A cartoon de-
piction is shown in Fig. 1; for k = 2, this corresponds
to the standard two-stage model with clonal expansion
(TSCE).
The mathematical model above can be solved for
the survival function S(t) and, equivalently, the hazard
(here: lung-cancer mortality rate), h = − ddt lnS, using
the method of characteristics [41]. For the two-stage
model, assuming rate parameters to be piecewise age-
independent, an exact closed-form solution can be at-
tained [42]. In the general case, an extension of this so-
lution is valid approximately if age bins are small enough
for intermediate-cell numbers to change slowly.
As an illustration, let us highlight some generic fea-
tures shared by all such multistage models. At earlier
ages, the hazard is well described by a deterministic
model, h ≃ µk−1X¯k−1, in terms of the mean numbers of
cells, ˙¯Xj = µj−1X¯j−1 + γjX¯j [41]. This leads to an ini-
tially polynomial growth, h(t) ≃ Nµ0 · · ·µk−1t
k−1/(k −
1)!, followed by a rapid proliferation-driven phase, h(t) =
O(eγt), where γ denotes the maximum growth rate. How-
ever, this deterministic approximation fails to account for
the effective reduction in available premalignant cells as
new malignancies arise: Whenever a person reaches the
cancer endpoint, those cells can no longer lead to fur-
ther cancer cases. At older ages, approximately around
the mean cancer age, a steady state is reached between
growth and effective “loss” of premalignant cells [41], and
the hazard levels off to a constant limit, h∞ ∼ Nµ0γ1/α1.
These borderline cases also illustrate a more general
point: Not all biological rates can be determined from
fits to the cancer data alone. Generically, only certain
parameter combinations are identifiable [43].
In the discussion so far, we have tacitly assumed a lin-
ear series of transitions for simplicity. However, we also
test a model where mutations may occur along two dif-
ferent pathways, as sketched in Fig. 1(bottom). Such a
model has been introduced by Little et al. [10] to account
for genomic instability, inspired by models for colon can-
cer [14]. The underlying idea is that a second path, ac-
tivated via transition rates σj , corresponds to the loss of
a gene involved in maintaining genomic integrity. This
may lead to mutation rates much larger than for the ge-
nomically stable (upper) path, µGIj ≫ µj [44]. Despite
the more complex topology, the model equations are con-
structed and solved using exactly the same principles as
outlined above.
2. Risk modeling
In the framework of multi-stage models, the hazard is
fully determined by the (generally time-dependent) mu-
tation and growth rates. These parameters are essen-
tially assumed to have an age-independent background
value which may be modified by external risk factors such
as radiation dose rate, d(t), and smoking, s(t), here as-
sumed to start from 18 years on. In practice, both risk
factors are allowed to independently increase any of the
rate parameters ϑl ∈ {µ0, µ1, . . . , γ1, . . .}; from all possi-
ble combinations {ϑl(d), ϑl′ (s)}, the best-fitting model is
selected. Depending on which of these rates show a ra-
diation effect, the radiation risk varies in a characteristic
fashion with age [42], as well as with modifiers such as
duration of or age at exposure.
This is in marked contrast to conventional descriptive
models employed in radiation epidemiology [45], which
we also use to benchmark our results. In a descriptive
model, the hazard function is modeled directly – rather
than its underlying mechanism. Here we use the conven-
tional parametrization [37]
h(t) = hbsl(t) [1 + ERR(D, t, . . .)] , (1)
where the baseline, hbsl(t) = e
ψ(t)+ψrf , is factored
into terms for age-dependent background, ψ(t) ≡∑2
j=0 cj ln
j( t60a ), and other risk factors, ψrf (birth year,
smoking and alcohol, etc.). The excess relative risk,
ERR, is factored into dose-response shape—typically
a function of cumulative dose, D(t − tlag)—and time-
dependent modifiers such as attained age or age at expo-
sure, see Appendix.
3. Fit procedure
All model parameters are estimated by maximizing
their likelihood L, which is constructed using the indi-
vidual likelihoods of all cohort members [46]. Equiva-
lently, we minimize the deviance, D = −2 lnL > 0, us-
ing the Minuit function-minimization library [47]. For
4Table I: Synopsis of the best models in this study, along
with figures of merit for their goodness of fit (see text
for details). The columns labeled d and s indicate the
model’s parametric dependence on dose(rate) and
smoking-related confounders; e.g., γ = γ(0)(s) + δγ(d)
for the TSCE model.
Model s d # Parametersa Deviance AIC
descriptive ψcf ERR(D) 9 4770.3 4788.3
TSCE γ γ 10 4760.7 4780.7
3SCE(A) µ1 γ1 11 4749.9 4771.9
3SCE(B) γ2 γ1 11 4756.7 4778.7
3SCE(C) γ1 γ2 11 4757.7 4779.7
aCounting parameters for background, smoking/alcohol,
birthyear , and Pu; see Appendix.
model selection, we rely on the likelihood-ratio test for
nested models so as to retain only parameters signifi-
cant at a 95% confidence level. The same level is also
adopted throughout this paper for confidence intervals.
To rank non-nested models, the entropy-based Akaike in-
dex is used [48], AIC = D+2n, which effectively penalizes
overfitting for models with larger number of parameters
n.
III. RESULTS
Table I provides an overview of the best-fitting mod-
els. Before explaining in detail their mechanisms and
the implications for radiation risk, let us anticipate some
general patterns. All highest-ranked multi-stage mod-
els share a Plutonium-induced enhancement of prolifera-
tion rates. More specifically, the fits suggest that 3-stage
models with a radiation effect on an early stage of prolif-
eration (models A, B) may yield an improved description
of the Mayak data, compared with an effect on the penul-
timate stage (C). Although model A exhibits by far the
lowest AIC, we will present the radiation risks for sev-
eral three-stage models so as to give an impression of the
range of model predictions, as discussed in the Appendix.
No evidence is found for a radiation-induced second
pathway. We note that all dose rates here refer to internal
Pu exposure; external radiation is not significant in two-
stage and descriptive models and thus not considered in
the following.
A. Two-stage model
The two-stage model has been applied to previous
follow-ups of the Mayak workers [31, 32]. We shall there-
fore discuss it here as a benchmark, but also to illustrate
some mechanisms inherent in any multistage model.
Smoker
Non-smoker
0.1 0.2 0.3 0.4 0.5
d HGyaL
0.1
0.2
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Γ Ha-1L
Figure 2: Dependence of the proliferation rate, γ(d), on
internal (lung) dose rate in the TSCE model. For
comparison, the dots illustrate the results of a
categorical fit (with 95%-level errors).
We find that the effects of both Pu dose rate as well
as smoking status are by far best described as addi-
tively enhancing the net proliferation rate, γ(s, d) =
γ(0)(s) + δγ(d).[70] A categorical fit of the dose depen-
dence strongly suggests a saturation at larger dose rates
(Fig. 2), and we find it best modeled by an exponentially
leveling function
δγ(d) = γ∞
(
1− e−r×d/γ∞
)
. (2)
Here r ∼ 5/Gy (see Table III) governs the linear, low-
dose response, δγ ∼ r d, and γ∞ ∼ 0.3/a denotes the
rate approached as d≫ d∗ ≡ γ∞/r; here d∗ ∼ 0.06Gy/a.
This is qualitatively in line with previous analyses [31,
32] but also several Radon-risk studies [23, 25, 27, 29,
30], see Discussion. It is worth noting that the data fit
equally well to a response in terms of the accumulated
dose D – i.e., δγ(D) in (2) – which may relate to the long
protracted exposures of Mayak workers.
It should be stressed that, even though the main risk
factors, smoking and Plutonium, enter the growth rate
additively, the actual risk will exhibit an interaction be-
tween them. To illustrate this, in Fig. 3a we display the
age-dependent hazard, h(t), for a representative exposure
scenario at a constant dose rate from age t1 = 25a to 60a,
with dose D = 0.2Gy. For a wide age range, coinciding
with the phase of exponential proliferation, the relative
risks of radiation and smoking approximately multiply
(note the log scale). It is only at larger ages (& 60a) that
the combined risk drops below the multiplicative value.
Such sub-multiplicity agrees with trends glimpsed in a de-
scriptive analysis [37]. Here, it follows naturally because
the hazard of Pu-exposed smokers levels off much earlier,
reflecting an earlier onset of cancer (see Methods).
To better link these findings to those of descriptive
models (see Appendix), we will from now on consider
the excess relative risk, ERR ≡ h/hbsl − 1, defined rela-
tive to the zero-exposure baseline risk. From this angle,
multiplicity of risk implies an equal ERR for smokers and
non-smokers – i.e., a ratio ERR(s=1)/ERR(s=0) = 1. Fig-
ure 3b shows that, under the scenario above, the risk is
indeed multiplicative until older ages (t . 60a). It then
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(a) Hazard h(t) of the two-stage model for
non-/smokers. Shown are values without (baseline)
and with exposure. (Smoking is assumed to start at
age 18.)
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(b) Excess-relative-risk (ERR) ratio of smokers and
non-smokers, shown for different multi-stage models
(see text). A ratio of 1 indicates multiplicative
Plutonium-smoking interaction, as in the standard
descriptive model. The thin-dotted line denotes the
(non-significant) sub-multiplicative trend suggested
by an extended descriptive model.
Figure 3: Risk for a scenario with constant exposure
between ages 25 and 60, at D = 0.2Gy. Notice the lag
time of 5a.
becomes sub-multiplicative, and the ERR ratio drops
markedly below unity after (time-lagged) exposure ends.
Since most cases are related to smoking, we will now
concentrate on the risk for smokers. Moreover, to sep-
arate age and dose dependencies, we scale the ERR by
the accumulated dose, ERR(D; t)/D(t − tlag), with the
lag time tlag = 5a. Figure 4 displays the age-dependent
ERR/D for the scenario above but at D = 0.5Gy. For
the two-stage model, it reveals a characteristic increase
during exposure (owing to proliferation), followed by a
marked drop-off after exposure has ended. The latter is
similar to the (non-significant) attained-age trend found
in the descriptive model, cf. Appendix.
The age dependence just discussed pertains to one spe-
cific scenario. Let us now indicate how the risk is mod-
ified by different exposure patterns. The dependence
upon age at first exposure, t1, is shown in Fig. 5a. We
have chosen a scenario with D = 0.2Gy and a typical du-
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Figure 4: Age-dependent excess relative risk (ERR/D)
of different multi-stage models, for smokers with
constant exposure between ages 25 and 60 (D = 0.5Gy).
For comparison, the non-significant trend in the
descriptive model (thin-dotted line) is also shown. (All
error bars are at 95% confidence level.)
ration ∆t = 20a; the ERR is recorded at t1 +∆t + tlag.
Clearly, for this two-stage model, the variation is rather
mild for all but very early exposures (not encountered at
Mayak) and very late ones. In the former case, virtu-
ally no premalignant cells are available for proliferation.
At older ages, in turn, they are increasingly lost to new
malignancies; thus the risk is attenuated. In the descrip-
tive model, a weak (non-significant) trend also suggests a
slight decrease of ERR with older ages at exposure (not
shown).
Figure 5b reveals a characteristic influence of exposure
duration, ∆t (where D = 0.2Gy, t1 = 20a). For very
short exposures, ∆t ≪ D/d∗ ∼ 3a, the ERR is strongly
suppressed: The short duration cannot be compensated
by an increased dose rate, since the growth rate satu-
rates at dose rates larger than d∗. This inverse dose-
rate effect is thus inherently connected to a saturating
radiation response as in Eq. (2). It has been observed
also in mechanistic Radon studies [23, 25, 30], although
the Mayak data are not powerful enough to support this
at the descriptive level. At sufficiently long exposures,
∆t ≫ D/d∗, the inverse dose-rate effect disappears and
eventually gives way to a slight direct effect. This is
related to the leveling of the hazard upon reaching ma-
lignancy.
To wrap up this discussion, let us consider the dose-
response relationship implied by this proliferation-based
model. Figure 6 illustrates that, in contrast to the linear
dose response typically assumed in descriptive modeling
(ERR(D) = cD, here c ≈ 4.7/Gy), this model exhibits
a nonlinear response. Although the quantitative values
depend on the exposure scenario (here: exposure during
t = 25 − 60a), some general features apply to any two-
stage model with a proliferation enhancement similar to
Eq. (2): The dose response is characterized by a lin-
ear low-dose regime, ERR ≃ r × D for D ≪ 1/r, and
leveling at sufficiently large dose(rate)s and/or ages. In-
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Figure 5: Dependence of ERR/D on different exposure
patterns, for smokers with D = 0.2Gy.
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Figure 6: Dose-response relationship, ERR(D), for
exposure during ages 25 to 60, recorded at age t = 65.
For comparison, the linear response ERR = cD is
plotted.
termittently, typically an exponential increase is seen, re-
flecting the exponential growth of premalignant cells due
to proliferation. However, this effect tends to be washed
out by the leveling at older ages. In a descriptive model
fit, where essentially an averaging occurs over all expo-
sure histories in the cohort, this pronounced nonlinearity
will be even harder to resolve. Still, it is noteworthy that
a TSCE-inspired descriptive model, ERR = ef(D) − 1
with f(D) ≡ c∞(1 − e
−clinD/c∞), yields an improved fit
(but similar AIC), with a linear response clin ∼ 3.2/Gy
and leveling at D∗ ≡ c∞/clin ∼ 0.8Gy.
B. Three-stage models
As mentioned earlier, the highest-ranked 3-stage mod-
els fall into two categories.
The best two models (A, B; see Table III) show a radia-
tion effect on the earlier stage of proliferation, γ1(d), dif-
fering only in their background parameters – specifically
the smoking response on µ1 (A) or γ2 (B). This early im-
pact leads to a substantially delayed radiation response
compared to both the 2-stage model and 3-stage model
C, as is seen from Fig. 4: The ERR/D is initially zero
and, once it has peaked, tends to drop off more mildly.
(In some scenarios, the ERR/D may even increase when
exposure stops.) This lag is intuitive, as the insulted
cells need to pass through an additional mutation stage
before becoming malignant. In stark contrast, model C—
with an effect on the penultimate stage—predicts a much
higher risk, ERR/D ≃ r ∼ 10/Gy, right after exposure.
In the scenario depicted in Fig. 4, it further displays an
almost monotonic drop with attained age, not unlike the
trend seen in the descriptive model risk.
However, it must be stated that this specific scenario
conceals an underlying complexity not present in the 2-
stage model. The reason is that the 3-stage model is
determined by two competing growth rates, γ1 and γ2.
Let us consider models A/B: For a small enough dose rate
such that γ
(0)
1 +rd < γ
(0)
2 , the clonal dynamics is governed
by the largest baseline rate, γ
(0)
2 . In other words, below
the critical dose rate dcrit ≡ (γ
(0)
2 − γ
(0)
1 )/r∼ 0.01Gy/a,
both baseline and excess risk grow with the same expo-
nential rate – hence the ERR would level off with age. It
is only above that critical dose rate that an exponential
increase is seen in the ERR. Likewise, for model C, the
critical point, (γ
(0)
1 − γ
(0)
2 )/r, marks the dividing line be-
tween exponential increase and leveling with age. Notice
that the value in Fig. 4 is just at the borderline.
The dose-rate dependence just described is reflected in
the dose response (Fig. 6). At low doses, a linear increase
is seen, just as for the two-stage model. However, that
low-dose response is typically much lower than what we
saw for two-stage and descriptive models. It is only at
the critical dose, here dcrit∆t ∼ 0.35Gy, that a rapid
exponential increase sets in. Compared to the two-stage
case, this exponential increase is much sharper owing to
the higher response coefficients, r ∼ (10 − 17)/Gy. As
before, the response levels off once the corresponding dose
rates exceed d∗ ∼ (0.03− 0.05)Gy/a.
Another consequence of an early-stage radiation effect
is a notably suppressed risk for older ages at exposure, t1
(Fig. 5a). To understand this, recall that the radiation
7effect consists in multiplying the available pool of stage-
1 cells, X1(t1), prior to their making the transition to
stage 2. Since that number grows only very slowly at a
rate γ
(0)
1 < γ
(0)
2 , the head start given to already existing
stage-2 cells, X2(t1), becomes overwhelming the later in
life exposure starts. Thus the ERR is suppressed expo-
nentially as e−(γ
(0)
2 −γ
(0)
1 )t1 for large t1. By contrast, the
mechanism for model C is fairly similar to that of the
2-stage model: Both radiation and baseline risk are gov-
erned by the growth of existing stage-2 cells. This is why
virtually no dependence on t1 is seen other than a mild
drop-off for older ages at exposure, due to the onset of
malignancies.
Differences with respect to the two-stage model may
also be observed in the exposure-duration dependence
(Fig. 5b). Like the 2-stage models, all 3-stage models
exhibit an inverse dose-rate effect for durations ∆t .
D/d∗. As explained previously, this merely hinges on the
saturation of the proliferation rate for higher dose rates.
It may be noted that the early-stage models A/B lead to
a stronger risk suppression at such short durations, due to
the extra mutational step to be passed. However, a more
qualitative difference is found for longer durations: Here
a marked direct effect occurs, the ERR falling off as∆t−1.
This may be viewed as a linear dose-rate modification for
perturbatively small dose rates D/∆t in the limit of long
durations.
Finally, let us comment on the interaction between
radiation and smoking risks. We saw earlier that the
two-stage model predicts a largely multiplicative inter-
action or, equivalently, a near-unit ratio of smokers’
and non-smokers’ ERR (Fig. 3b). The situation is less
clear cut for the three-stage models. Model C, with a
later-stage radiation effect, is most comparable to the
2-stage case: Initially, it also exhibits near-multiplicity,
which reflects that radiation simply leads to multipli-
cation of existing stage-2 cells. However, the ERR ra-
tio then drops very rapidly. This is essentially because
for smokers, the dose rate is below the critical value,
(γ
(0)
1 − γ
(0)
2 )/r ∼ 0.01Gy/a, as smoking leads to a very
large growth rate γ1(s = 1) ≈ 0.16a
−1. Thus the ERR
levels off, in contrast to the exponentially growing ERR
for non-smokers, where there is no threshold. An anal-
ogous mechanism is at work in the model B, which is
sub-multiplicative throughout.
By contrast, for model A, the risk in the scenario shown
in Fig. 3b is strikingly super-multiplicative except for
ages t & 70a. At first glance, this deviation from mul-
tiplicity might seem surprising: For constant rates, the
hazard is typically proportional to µ1(s), and the smok-
ing dependence should thus drop out of the relative risk.
However, smoking is assumed to start at age 18, only a
few years prior to irradiation. Hence the baseline risk—
initially proportional to the number of existing stage-2
cells—mostly stems from those cells created before smok-
ing started, and is thus comparable for non-/smokers.
Thus, the large ERR for smokers reflects the much higher
excess risk due to freshly mutated stage-1 cells. It is only
long after the start of exposure that the smokers’ baseline
risk increases sufficiently to compensate for this.
C. Two-pathway models
We have tested a family of multi-path models of ge-
nomic instability (GI). Let us briefly outline the key as-
sumptions made here to reduce the number of parame-
ters – in total, 6 mutation rates and 6 cell-division/death
rates, as sketched in Fig. 1. Most premises are moti-
vated by the biological mechanisms thought to underlie
GI [14, 44]. First, the destabilizing transition rates are
set equal, σj ≡ σ, as they pertain to the inactivation of
the same genomic-integrity gene. Since, presumably, GI
per se does not lead to any growth advantage, we set the
birth/death rates at stage 0GI equal, αGI0 = β
GI
0 , their
precise value being marginal. Mutation rates following
GI, µGIj , are supposed to be larger, or at least equal, com-
pared to their genomically stable (upper-branch) coun-
terparts.
Although GI may well be present as a sporadic mecha-
nism, the baseline data are not thought to provide suffi-
cient structure to distinguish complex background mod-
els (see Discussion; cf. also Ref. [15]). We have thus
focused on the case of radiation-induced GI – i.e., an ac-
tivation of the otherwise silent GI path (σ) by radiation.
This may be modeled as σ = rGI × d (with vanishing
background rate). In addition, radiation may affect reg-
ular mutation or growth rates.
None of the tested two-pathway models has led to any
significant, numerically stable improvement beyond the
benchmark two-stage model. It is stressed that relaxing
the assumptions of linearity or vanishing background rate
do not yield a significant improvement.
IV. DISCUSSION
A. Mechanism of radiation action
A robust result of our analysis is an α-radiation-
induced enhancement of proliferation rates of premalig-
nant cells. This corroborates a consistent finding in many
studies based on fitting two-stage models to lung-tumor
data, both from epidemiological cohorts (Radon-exposed
miners [23, 25, 27, 29, 30]) and animal experiments (see
Ref. [49] for an overview). It also alleviates concerns that
a proliferation effect might be confined to the two-stage
model [34].
However, it has long been criticized [33] that no ra-
diobiological evidence exists for such a premalignant-
growth-enhancing effect. Although experimental evi-
dence is still sparse [50, 51], let us briefly discuss some
theoretical models put forward to explain how radia-
tion might lead to enhanced proliferation of premalignant
cells.
8Table II: Observed numbers of lung-cancer cases by dose categories, compared with those predicted by the
descriptive and multi-stage models (in brackets: excess cases). As a reference, we also give the person years (py).
Doses (Gy) py Cases TSCE 3SCE(A) 3SCE(B) 3SCE(C) descriptive
0− 0.01 188, 995 204 198 (0.5) 203 (0.2) 205 (0.2) 204 (0.3) 194 (0.6)
0.01 − 0.03 18, 888 32 50 (3) 49 (1) 50 (1) 50 (1) 49 (4)
0.03 − 0.1 15, 843 58 51 (9) 47 (4) 47 (4) 48 (4) 52 (11)
0.1 − 0.3 7, 091 41 37 (15) 31 (8) 30 (23) 31 (7) 39 (17)
0.3− 1 3, 153 29 33 (24) 34 (25) 31 (21) 31 (21) 32 (23)
> 1 738 24 18 (16) 24 (21) 25 (22) 25 (22) 22 (20)
total 234, 708 388 388 (67) 388 (59) 388 (56) 388 (56) 388 (75)
The most elaborate model is based on the following
idea [52]: Radiation kills cells, which in turn triggers di-
vision of neighboring stem cells so as to replenish the
lost tissue. This may lead to net proliferation of prema-
lignant cells if these have a selective advantage, that is, a
slightly higher rate for cell division than needed for home-
ostasis. (Strictly speaking, cells need not necessarily be
killed; it might be sufficient for them to have a prolif-
erative disadvantage—e.g., by effected cell-cycle arrest—
such that these are subsequently repelled by premalig-
nant cells.) That hypothesis has been shown [53–55] to
lead to a dose-rate response, γ(d), which is qualitatively
similar to that found in cohort studies (see, e.g., Fig. 2),
albeit with quantitatively modest agreement. Saturation
of the growth rate much higher than a characteristic dose
rate, d ≫ ds, occurs if more cells are killed than can be
substituted for by premalignant cells.
To obtain a very rough estimate for that critical dose
rate, note that α-particle hits of a cell nucleus are in-
dependent and rare. Thus the number of hits, N , is
Poisson-distributed, PN = e
−N¯ N¯N/N !, which means the
fraction of cells not hit is PN=0 = e
−N¯ . Assuming (i) a
linear dose response, N¯ = nD, with n ∼ 4/Gy [56], and
(ii) delivery of the dose D ≡ d τ over a characteristic
time of order the interval between cell cycles (τ ∼ 1a
for basal stem cells [57]), we have PN=0(d) = e
−ndτ . At
the characteristic dose rate, ds, about one out of, say, six
nearest neighbors would be hit, such that P0(ds) = 1−p,
p ≡ 1/6, yielding a characteristic dose rate of
ds ≃
p
nτ
∼ 0.04
Gy
a
. (3)
This is on the same order of magnitude as the value found
in this study, d∗ ∼ (0.03 − 0.06)Gy/a. In this light, the
model results presented here and the repopulation mech-
anism may be interpreted to be compatible. However,
it is important bearing in mind that these estimates are
naturally crude. Matters are further complicated by the
spatially inhomogeneous energy deposition within differ-
ent spots in the lungs, an effect not reflected in whole-
lung doses used here [58].
As an alternative mechanism, a radiation-induced
disturbance of cell communication has been suggested
[9, 59]. This may lead to, e.g., up-regulated growth sig-
nals or a reduction of apoptosis [60, 61], with a higher
effect on intermediate cells because those tend to evade
homeostatic control. It has even been proposed that a
proliferation enhancement, mediated by such a bystander
signaling, might be the generic mechanism for the re-
sponse to densely ionizing radiation [62]. However, no
mechanistic model has been put forward explaining in
detail how this might lead to a dose-rate response, γ(d).
Even so, should the radiation response indeed be gov-
erned by the bystander effect, then a similar behavior
ought to be expected as for bystander-mediated muta-
tion induction [63]. In microbeam experiments [64, 65],
it has been found that for low doses—corresponding to
less than ∼ 10% of cells being hit—the mutagenic yield
was strongly amplified as bystander cells also received
signals. (A similar pattern has been found for inter-
cellular induction of apoptosis [66].) For much higher
doses, in turn, the response essentially saturated. Along
the lines leading to Eq. (3), we can estimate the char-
acteristic dose rate ds by assuming the crossover to oc-
cur at a fraction p = 0.1 of cells being hit. This yields
ds ≈ p/nτ ∼ 0.025Gy/a, under the same caveats as men-
tioned above. From this standpoint, both bystander sig-
naling and the repopulation hypothesis appear compati-
ble with the dose-rate response found in this study.
B. Comparison with previous studies
As discussed earlier on, for mechanistic models, the
risk is essentially determined by its structure, particu-
larly, the radiation response. A dose-rate dependent pro-
liferation rate, γ(d), saturating for larger dose rates (as
in Eq. 2) is found in many studies applying the two-stage
model to α-particle-induced lung cancer. In particular,
this response quantitatively agrees with that of the pre-
ferred two-stage model by Jacob et al. for the Mayak
cohort, both for Plutonium and smoking [32]. Concor-
dantly, their risk estimates are similar to those of the
present TSCE model – such as a cohort-averaged excess
risk of ERR(t = 60a)/D ∼ 4/Gy, a nonlinear dose de-
pendence ERR(D) for larger doses, and sub-multiplicity
of smoking and radiation risks.
In a recent descriptive analysis of the Mayak data,
9Gilbert et al. found a linear dose response, modified sig-
nificantly only by a drop-off with attained age ([37], see
also Appendix). The value at age 60, ERR(t = 60a) ∼
7D/Gy, is somewhat higher than for the cohort average
of the mechanistic models presented here. By contrast,
the multi-stage models exhibit a strongly nonlinear dose
dependence especially for higher doses. Furthermore,
they typically display a decrease with attained age only
for large enough ages, most pronounced after the end of
exposure. Initially, an increase with age is seen due to
exponential clonal growth, at least for high enough doses.
In contrast to descriptive models, where an exposure
modifier may not be significant when parametrized ex-
plicitly, mechanistic models implicitly make predictions
for the risk dependence on any exposure scenario. This is
exemplified by the age-at-exposure dependence or the in-
verse dose-rate effect shown by (at least some) mechanis-
tic models (Fig. 5). Furthermore, a non-significant trend
in Ref. [37] indicated a sub-multiplicative interaction be-
tween Plutonium dose and smoking. This is in agreement
with results from the 2-stage model, which further offers
a mechanistic interpretation in terms of exponential cell
growth, combined with earlier malignancies for smokers
(see Results).
C. Implications for lung carcinogenesis
We have shown that several three-stage models give
an improved description of the data compared to one in-
volving two stages. Evidently, this stochastic inference
is based solely on the lung-cancer endpoint and cannot
replace experimental insight into the dynamics of inter-
mediate stages. Even so, it is worth emphasizing that
the Mayak data do not fully allow to distinguish general
mechanisms for carcinogenesis. Rather, the results here
mostly rely on the radiation-associated risk. In fact, the
deviances of the various mechanistic and descriptive base-
line models (risk factors age and smoking) do not differ
noticeably – in contrast to the models including exposure
(Table I).
That statement seemingly contradicts the fact that
there is only a fraction ∼ 25% of excess cases relative
to the baseline (as can be seen from ERR ∼ 5D¯/Gy,
the whole-cohort average dose being D¯ ∼ 0.05Gy). This
translates to 60 − 70 excess cases (Table II), compared
to about 320 baseline cases. However, truly spontaneous
baseline cases (30 − 40) are outnumbered by smoking-
related ones by a factor of ∼ 10. Moreover, the smoking
variable is only binary (and noisy). This makes it hard
to resolve the actual baseline risk accurately, especially
since the multi-stage models do not differ in their quali-
tative behavior except for young ages. By contrast, the
models do differ markedly for different irradiation sce-
narios as found in the Mayak data.
V. CONCLUSION
We have shown that carcinogenesis models extended to
three stages offer an improved description of the Mayak
lung-cancer data, as compared to the two-stage model.
All favored 3- and 2-stage models indicate a radiation-
enhanced proliferation rate of premalignant cells, sug-
gesting that this is a robust finding not limited to the
framework of two stages. Despite that structural simi-
larity, the models make qualitatively different predictions
for the risk following certain exposure scenarios. For in-
stance, those models whose radiation impact is on an
earlier stage exhibit a strongly suppressed risk for older
ages at exposure. As opposed to the two-stage case,
all three-stage models reveal a soft-threshold dose(rate)
above which the excess risk increases sharply. More-
over, while an inverse dose-rate effect is predicted by all
models, only those with three stages also display a pro-
nounced direct effect for longer exposure durations.
One aim of this study has been to elucidate which as-
pects of carcinogenesis models are persistent themes or
rather model-specific features. Such a better understand-
ing should facilitate the development of improved car-
cinogenesis models, both mechanistic but also descrip-
tive ones. There is still some way to go toward a more
realistic description. Ultimately, this would involve bi-
ological input on rates or premalignant stages so as to
cut the number of undetermined parameters. Closer at
hand, a natural next step may be validating the current
models on other data sets. An extension to more than
three stages conceivably provides a further improvement.
Moreover, to get a more accurate description of the bi-
ological mechanisms, it is desirable to develop models
specifically for the different histological cancer subtypes.
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Appendix A: Parameter estimates
We now present some details on the model results.
The reference descriptive model closely follows
Ref. [37]. The main risk factor is smoking, which is in-
cluded simply as a factor in Eq. (1), eψsmk = e2.3±0.3 ≈
10. The alcohol status further increases the baseline risk
by eψalc = e0.6±0.1 ≈ 1.8. In addition, the birth year was
found to elevate the risk between years 1915 and 1935
by about e0.4±0.1 ≈ 1.5. With 3 extra parameters, this
birth-cohort effect is moderately significant (∆D = −11).
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It might be interpreted as a smoking modifier (as which
it yields only a slightly higher deviance), possibly related
to the changed smoking levels between the wars. The
effect is irrelevant for the radiation risk, and generally
no birth-cohort distinction is made in the scenarios in
Figs. 3–6. We mention that a calendar-year dependence
has been tested but discarded: It oscillates strongly but
shows no conclusive trend, nor does it influence the dose
response.
The dose dependence is modeled as a linear function,
ERR = cD, c = (4.7 ± 0.9)Gy−1, with no evidence for
threshold or quadratic terms. Note that the lag time
entering the dose, D ≡ D(t − tlag), does not alter the
deviance significantly between 0 − 10a. We fix it at
tlag = 5a, also for all multi-stage models. No signif-
icant time-dependent dose modifiers are found. How-
ever, a trend suggests a decrease of ERR/D with at-
tained age, modeled as (t/60a)−2.4±2.5, and a marginal
decrease with median age at exposure. Even though the
reference model (1) implies multiplicative risks of smok-
ing and radiation, a non-significant trend indicates sub-
multiplicity, with an ERR for smokers reduced by a factor
e−0.9(±1.5) ∼ 0.4.
The maximum-likelihood parameters of the TSCE
model are shown in Table III. We have omitted two co-
variables not relevant for the radiation risk: alcohol and
birth year. Both are included as addends to the growth
rate γ, consistent with an interpretation as smoking sur-
rogates. We have also tested an explicit age dependence
of the rate parameters, which indicated a reduction of
µ1(t) or, equivalently, γ(t) above age ∼ 50a. However,
these effects were numerically unstable and have thus
been discarded. To convey an impression of the fit qual-
ity, Table II shows a juxtaposition of observed cancer
cases and those predicted by the various models across
the dose range.
A comment is in order on the parameter estimates
of the three-stage models (Table III). Some of the
(structurally) identifiable parameter combinations may
be practically indeterminable insofar as they leave the
minimum deviance D virtually unchanged. In model A,
e.g., D is independent of µ1µ2 → 0, which has been fixed
at an arbitrarily small value. Furthermore, the best esti-
mate of γ
(0)
1 = α1 − β1 ≈ −0.1a
−1 is not significant and
γ
(0)
1 thus is set to zero. Worse yet, for model B (C), the
background rate γ
(0)
2 (γ
(0)
1 ) is unstable, tending to unre-
alistically large negative values. Since only the smokers’
value is stable, γ
(0)
2 +∆γ2(s = 1) ∼ 0.1a
−1, we have set
γ
(0)
2 ≡ 0, even at the price of a higher deviance. It is also
for these intricacies that we have opted to present sev-
eral of the best three-stage models, rather than relying
strictly on the weight suggested by Akaike’s index. This
way, a more plausible impression is given of the uncer-
tainty of model predictions.
[1] Weinberg R (2013) The Biology of Cancer. Garland Sci-
ence.
[2] Hanahan D, Weinberg RA (2011) Hallmarks of cancer:
the next generation. Cell 144: 646–74.
[3] Nordling C (1953) A new theory on the cancer-inducing
mechanism. Br J Canc 7: 68.
[4] Armitage P, Doll R (1954) The age distribution of cancer
and a multi-stage theory of carcinogenesis. Br J Canc 8:
1.
[5] Knudson AG (1971) Mutation and cancer: statistical
study of retinoblastoma. PNAS 68: 820–3.
[6] Moolgavkar SH, Venzon DJ (1979) Two-event models for
carcinogenesis: incidence curves for childhood and adult
tumors. Math Biosci 47: 55–77.
[7] Tan WY (2008) Handbook of cancer models with appli-
cations, volume 9. World Scientific.
[8] Little MP (2010) Cancer models, genomic instability and
somatic cellular Darwinian evolution. Biol Direct 5: 19;
discussion 19.
[9] Jacob P, Meckbach R, Kaiser JC, Sokolnikov M (2010)
Possible expressions of radiation-induced genomic insta-
bility, bystander effects or low-dose hypersensitivity in
cancer epidemiology. Mutat Res 687: 34–9.
[10] Little MP, Wright EG (2003) A stochastic carcinogenesis
model incorporating genomic instability fitted to colon
cancer data. Math Biosci 183: 111–134.
[11] Little MP (1995) Are two mutations sufficient to cause
cancer? Some generalizations of the two-mutation model
of carcinogenesis of Moolgavkar, Venzon, and Knudson,
and of the multistage model of Armitage and Doll. Bio-
metrics 51: 1278.
[12] Luebeck EG, Moolgavkar SH (2002) Multistage carcino-
genesis and the incidence of colorectal cancer. PNAS 99:
15095–100.
[13] Lengauer C, Kinzler KW, Vogelstein B (1997) Genetic
instability in colorectal cancers. Nature 386: 623–627.
[14] Nowak MA, Komarova NL, Sengupta A, Jallepalli PV,
Shih IM, Vogelstein B, et al. (2002) The role of chromo-
somal instability in tumor initiation. PNAS 99: 16226–
31.
[15] Little MP, Li G (2007) Stochastic modelling of colon can-
cer: is there a role for genomic instability? Carcinogen-
esis 28: 479–87.
[16] Little MP, Vineis P, Li G (2008) A stochastic carcino-
genesis model incorporating multiple types of genomic
instability fitted to colon cancer data. J Theor Biol 254:
229–38.
[17] Kaiser JC, Meckbach R, Jacob P (2014) Genomic insta-
bility and radiation risk in molecular pathways to colon
cancer. PLoS ONE 9: e111024.
[18] Meza R, Jeon J, Moolgavkar SH, Luebeck EG (2008)
Age-specific incidence of cancer: Phases, transitions, and
biological implications. PNAS 105: 16284–9.
[19] Luebeck EG, Curtius K, Jeon J, Hazelton WD (2013)
Impact of tumor progression on cancer incidence curves.
Cancer Res 73: 1086–1096.
[20] Hazelton WD, Clements MS, Moolgavkar SH (2005) Mul-
tistage carcinogenesis and lung cancer mortality in three
11
Table III: Key parameter estimates (including symmetric 95%-level uncertainties).
Parameter TSCE
Nµ0µ1 (a
−2) (3.9± 3.6) × 10−7
αµ1 (a
−2) (3.0± 2.0) × 10−6
γ (a−1) 0.062 ± 0.014
δγ(s) (a−1) 0.076 ± 0.009
r (Gy−1) 5.2± 1.1
γ∞ (a
−1) 0.30± 0.08
(a) Two-stage model
Parameter 3SCE(A) 3SCE(B) 3SCE(C)
Nµ0µ1µ2 (a
−3) (1.3± 1.6) × 10−9 (2.0± 2.6) × 10−8 (4.0± 4.2) × 10−8
α1µ1µ2 (a
−3) (1.0± 1.0) × 10−8 (1.2± 1.7) × 10−7 (4.7± 3.4) × 10−7
α2µ2 (a
−2) (8.4± 8.0) × 10−6 (0.7± 1.1) × 10−5 +0a
µ1µ2 (a
−2) +0 +0 (1.2± 1.4) × 10−6
α1 − β1 (a
−1) 0 (n.s.)b 0.068 ± 0.043 0 (n.s.)
γ2 (a
−1) 0.16 ± 0.03 0 (n.s.) 0.050 ± 0.043
(smoking) µ1 × e
3.6±0.8 γ2+(0.14 ± 0.03) a
−1 γ1+(0.16± 0.03) a
−1
r (Gy−1) 17± 7 10± 5 10± 4
γ∞ (a
−1) 0.54 ± 0.15 0.46 ± 0.15 0.39± 0.16
(b) Best three-stage models
aParameter not converged, set to arbitrarily small, positive value
(∼ 10−10).
bNot significant; set to zero.
cohorts. Cancer Epidemiol Biomarkers Prev 14: 1171–
81.
[21] Schöllnberger H, Manuguerra M, Bijwaard H, Boshuizen
H, Altenburg HP, Rispens SM, et al. (2006) Analysis of
epidemiological cohort data on smoking effects and lung
cancer with a multi-stage cancer model. Carcinogenesis
27: 1432–44.
[22] Meza R, Hazelton WD, Colditz GA, Moolgavkar SH
(2008) Analysis of lung cancer incidence in the nurses’
health and the health professionals’ follow-up studies us-
ing a multistage carcinogenesis model. Cancer Causes
Control 19: 317–328.
[23] Luebeck E, Heidenreich W (1999) Biologically based
analysis of the data for the Colorado uranium miners
cohort: age, dose and dose-rate effects. Radiat Res 351:
339–351.
[24] Leenhouts HP (1999) Radon-induced lung cancer in
smokers and non-smokers: risk implications using a two-
mutation carcinogenesis model. Radiat Environ Biophys
38: 57–71.
[25] Hazelton WD, Luebeck EG, Heidenreich WF, Mool-
gavkar SH (2001) Analysis of a historical cohort of chinese
tin miners with arsenic, radon, cigarette smoke, and pipe
smoke exposures using the biologically based two-stage
clonal expansion model. Radiat Res 156: 78–94.
[26] Brugmans MJP, Rispens SM, Bijwaard H, Laurier D, Ro-
gel A, Tomásek L, et al. (2004) Radon-induced lung can-
cer in French and Czech miner cohorts described with a
two-mutation cancer model. Radiat Environ Biophys 43:
153–63.
[27] Heidenreich WF, Tomášek L, Rogel A, Laurier D, Tir-
marche M (2004) Studies of radon-exposed miner cohorts
using a biologically based model: comparison of current
Czech and French data with historic data from China and
Colorado. Radiat Environ Biophys 43: 247–56.
[28] van Dillen T, Dekkers F, Bijwaard H, Kreuzer M,
Grosche B (2011) Lung cancer from radon: a two-stage
model analysis of the WISMUT Cohort, 1955-1998. Ra-
diat Res 175: 119–30.
[29] Heidenreich WF, Tomášek L, Grosche B, Leuraud K,
Laurier D (2012) Lung cancer mortality in the Euro-
pean uranium miners cohorts analyzed with a biologically
based model taking into account radon measurement er-
ror. Radiat Environ Biophys 51: 263–75.
[30] Eidemüller M, Jacob P, Lane RSD, Frost SE, Zablot-
ska LB (2012) Lung cancer mortality (1950-1999) among
Eldorado uranium workers: a comparison of models of
carcinogenesis and empirical excess risk models. PLoS
ONE 7: e41431.
[31] Jacob V, Jacob P, Meckbach R, Romanov Sa, Vasilenko
EK (2005) Lung cancer in Mayak workers: interaction of
smoking and plutonium exposure. Radiat Environ Bio-
phys 44: 119–29.
[32] Jacob P, Meckbach R, Sokolnikov M, Khokhryakov VV,
Vasilenko E (2007) Lung cancer risk of Mayak workers:
modelling of carcinogenesis and bystander effect. Radiat
Environ Biophys 46: 383–94.
[33] Brugmans MJ, Bijwaard H, Leenhouts HP (2002) The
overrated role of ‘promotion’ in mechanistic modelling of
radiation carcinogenesis. J Radiol Prot 22: A75.
[34] Little MP, Haylock RGE, Muirhead CR (2002) Modelling
lung tumour risk in radon-exposed uranium miners us-
ing generalizations of the two-mutation model of Mool-
gavkar, Venzon and Knudson. Int J Rad Biol 78: 49–68.
[35] Koshurnikova N, Shilnikova N, Okatenko P, Kreslov V,
Bolotnikova M, Sokolnikov M, et al. (1999) Characteris-
tics of the cohort of workers at the mayak nuclear com-
plex. Radiat Res 152: 352–363.
[36] Anspaugh L, Degteva M, Vasilenko E (2002) Mayak pro-
duction association: Introduction. Radiat Environ Bio-
phys 41: 19–22.
[37] Gilbert ES, Sokolnikov ME, Preston DL, Schonfeld SJ,
Schadilov AE, Vasilenko EK, et al. (2013) Lung cancer
risks from plutonium: an updated analysis of data from
the Mayak worker cohort. Radiat Res 179: 332–42.
[38] Khokhryakov VV, Khokhryakov VF, Suslova KG,
Vostrotin VV, Vvedensky VE, Sokolova AB, et al. (2013)
Mayak Worker Dosimetry System 2008 (MWDS-2008):
assessment of internal dose from measurement results of
plutonium activity in urine. Health Phys 104: 366–78.
[39] Vasilenko E, Khokhryakov V, Miller S, Fix J, Eckerman
K, Choe D, et al. (2007) Mayak worker dosimetry study:
an overview. Health Phys 93: 190.
[40] Moolgavkar S, Krewski D, Schwarz M (1999) Mechanisms
12
of carcinogenesis and biologically based models for esti-
mation and prediction of risk. IARC Sci Publ : 179.
[41] Moolgavkar SH, Dewanji A, Venzon DJ (1988) A stochas-
tic two-stage model for cancer risk assessment. I. The
hazard function and the probability of tumor. Risk Anal
8: 383–92.
[42] Heidenreich WF, Luebeck EG, Moolgavkar SH (1997)
Some properties of the hazard function of the two-
mutation clonal expansion model. Risk Anal 17: 391–9.
[43] Heidenreich W (1996) On the parameters of the clonal
expansion model. Radiat Environ Biophys 35: 127–129.
[44] Eidemüller M, Holmberg E, Jacob P, Lundell M, Karls-
son P (2015) Breast cancer risk and possible mechanisms
of radiation-induced genomic instability in the Swedish
hemangioma cohort after reanalyzed dosimetry. Mutat
Res 775: 1–9.
[45] Preston DL, Shimizu Y, Pierce Da, Suyama A, Mabuchi
K (2003) Studies of mortality of atomic bomb survivors.
Report 13: Solid cancer and noncancer disease mortality:
1950-1997. Radiat Res 160: 381–407.
[46] McCullagh P, Nelder JA (1991) Generalized linear mod-
els. Chapman & Hall, London, 2nd edition.
[47] James F, Roos M (1975) Minuit – a system for function
minimization and analysis of the parameter errors and
correlations. Cancer Causes Control 10: 343–367.
[48] Akaike H (1974) A new look at the statistical model iden-
tification. IEEE Trans Automat Contr 19: 716–723.
[49] Heidenreich WF, Brugmans MJP, Little MP, Leenhouts
HP, Paretzke HG, Morin M, et al. (2000) Analysis of lung
tumour risk in radon-exposed rats: an intercomparison of
multi-step modelling. Radiat Environ Biophys 39: 253–
264.
[50] Kopp-Schneider A, Haertel T, Burkholder I, Bannasch P,
Wesch H, Groos J, et al. (2006) Investigating the forma-
tion and growth of alpha-particle radiation-induced foci
of altered hepatocytes: a model-based approach. Radiat
Res 166: 422–30.
[51] Chao DL, Eck JT, Brash DE, Maley CC, Luebeck EG
(2008) Preneoplastic lesion growth driven by the death
of adjacent normal stem cells. PNAS 105: 15034–15039.
[52] Heidenreich WF, Atkinson M, Paretzke HG (2001)
Radiation-induced cell inactivation can increase the can-
cer risk. Radiat Res 155: 870–872.
[53] Bijwaard H, Brugmans M, Schöllnberger H (2006) Can
promotion of initiated cells be explained by excess re-
placement of radiation-inactivated neighbor cells? Ra-
diat Res 744: 741–744.
[54] Heidenreich WF, Paretzke HG (2008) Promotion of initi-
ated cells by radiation-induced cell inactivation. Radiat
Res 170: 613–7.
[55] Madas BG, Varga K (2014) Biophysical modelling of the
effects of inhaled radon progeny on the bronchial epithe-
lium for the estimation of the relationships applied in
the two-stage clonal expansion model of carcinogenesis.
Radiat Prot Dosim 159: 237–41.
[56] National Research Council (1999) Health Effects of Ex-
posure to Radon: BEIR VI. (Natl. Acad. Press, Wash-
ington, DC).
[57] Harley NH, Chittaporn P, Meyers OA, Robbins ES
(1996) A biological model for lung cancer risk from 222-
Rn exposure. Environ Int 22: 977–984.
[58] Balásházy I, Farkas A, Madas BG, Hofmann W (2009)
Non-linear relationship of cell hit and transformation
probabilities in a low dose of inhaled radon progenies.
J Radiol Prot 29: 147–62.
[59] Curtis S, Hazelton W, Luebeck E, Moolgavkar S (2004)
From mechanisms to risk estimation – bridging the
chasm. Adv Space Res 34: 1404–1409.
[60] Trosko JE, Chang CC, Upham BL, Tai MH (2005) Low-
dose ionizing radiation: induction of differential intracel-
lular signalling possibly affecting intercellular communi-
cation. Radiat Environ Biophys 44: 3–9.
[61] Kundrát P, Friedland W (2014) Impact of intercellular
induction of apoptosis on low-dose radiation carcinogen-
esis. submitted to Radiat Prot Dos .
[62] Shuryak I, Brenner DJ, Ullrich RL (2011) Radiation-
induced carcinogenesis: mechanistically based differences
between gamma-rays and neutrons, and interactions with
DMBA. PLoS ONE 6: e28559.
[63] Brenner DJ, Little JB, Sachs RK (2001) The Bystander
Effect in Radiation Oncogenesis: II. A Quantitative
Model. Radiat Res 155: 402–408.
[64] Sawant SG, Randers-Pehrson G, Geard CR, Brenner DJ,
Hall EJ (2001) The bystander effect in radiation oncogen-
esis: I. transformation in C3H 10T 1/2 cells in vitro can
be initiated in the unirradiated neighbors of irradiated
cells. Radiat Res 155: 397–401.
[65] Zhou H, Suzuki M, Randers-Pehrson G, Vannais D, Chen
G, Trosko JE, et al. (2001) Radiation risk to low fluences
of alpha particles may be greater than we thought. PNAS
98: 14410–5.
[66] Abdelrazzak AB, Stevens DL, Bauer G, O’Neill P, Hill
MA (2011) The role of radiation quality in the stimula-
tion of intercellular induction of apoptosis in transformed
cells at very low doses. Radiat Res 176: 346–355.
[67] Missing risk-factor information may be taken into ac-
count via additional categories. However, we found that
this does not reduced the fit errors due to the noise in-
troduced this way.
[68] This simplified single-cell picture does not explicitly in-
clude cellular interactions. In particular, non-stem cells
are not taken into account. Thus, space limitations are
not modeled, and cell growth is exponential rather than
logistic. By contrast the hazard is bounded as an in-
creased number of premalignant cells leads to more can-
cer cases, hence reducing the population at risk.
[69] Note that the precise genetic or histopathological mean-
ing of these (pre-)malignant stages is far from clear for all
but a few cancer types. Their number can be very large,
and the stages may even differ strongly between differ-
ent histological subtypes. The rates pertaining to these
stages are thus considered as giving effective time scales,
determined from fits to the data.
[70] Note that an additional radiation effect on the initiating
rate, µ0(d), is highly insignificant when fitted to the data
and thus not included in our model. This may be simply
due to lack of data power rather and does not imply
irrelevance of radiation-induced initiating events.
